title: Probiotics as an adjuvant treatment in Helicobacter pylori eradication therapy.
abstract: Over 80% of individuals infected with Helicobacter pylori (H. pylori) are asymptomatic. Increased resistance to antibiotics and decreased compliance to the therapeutic regimens have led to the failure of eradication therapy. Probiotics, with direct and indirect inhibitory effects on H. pylori in both animal models and clinical trials, have recently been used as a supplementary treatment in H. pylori eradication therapy. Probiotics have been considered useful because of the improvements in H. pylori eradication rates and therapy-related side effects although treatment outcomes using probiotics are controversial due to the heterogeneity of species, strains, doses and therapeutic duration of probiotics. Thus, despite the positive role of probiotics, several factors need to be further considered during their applications. Moreover, adverse events of probiotic use need to be noted. Further investigations into the safety of adjuvant probiotics to H. pylori eradication therapy are required.
authors.affiliation: Department of Gastroenterology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.
authors.forename: Xin Yan
authors.initials: XY
authors.lastname: Zhu
authors.affiliation: Department of Gastroenterology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.
authors.forename: Fei
authors.identifier: http://orcid.org/0000-0003-3684-0944
authors.initials: F
authors.lastname: Liu
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004359:Drug Therapy, Combination; D016481:Helicobacter Infections / Q000628:therapy*; D016480:Helicobacter pylori; D006801:Humans; D019936:Probiotics / Q000627:therapeutic use*
chemical_list: D000900:Anti-Bacterial Agents
keywords: 
  Helicobacter pylori
  ; eradication; probiotics; therapy